| Name | N-[4-[[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide,hydrochloride |
|---|---|
| Synonyms |
ATC0175
N-(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide HCl |
| Description | ATC0175 is a potent, selective and orally active melanin-concentrating hormone 1 recepter antagonist with IC50s of 13.5, >10000 nM for MCH1R, MCH2R, respectively. ATC0175 shows antidepressant effects and anxiolytic effects in animal models. ATC0175 has the potential for the research of depression and/or anxiety disorders[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 13.5 nM (MCH1R); >10000 nM (MCH2R)[1]. |
| In Vitro | ATC0175 shows affinity for 5-HT2B and 5-HT1A with IC50s of 9.66 and 16.9 nM respectively[1]. |
| In Vivo | ATC0175 (1, 3, 10 mg/kg; p.o.) significantly and dose-dependently reduces immobility time, indicating antidepressant like potential[1]. |
| References |
| Molecular Formula | C23H26ClF2N5O |
|---|---|
| Molecular Weight | 461.93500 |
| Exact Mass | 461.17900 |
| PSA | 70.15000 |
| LogP | 5.39300 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335-H413 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| RIDADR | NONH for all modes of transport |